Obinutuzumab

奥妥珠单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameObinutuzumab
Drug Alias NameAfutuzumab奥比妥珠单抗阿托珠单抗GazyvaGazyvaro +[14] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsCentral Nervous System LymphomaRichter's SyndromeGraft vs Host Disease +[23] 
Global Approved IndicationsLymphoma, FollicularLeukemia, Lymphocytic, Chronic, B-Cell
Approved Indications in ChinaLymphoma, Follicular
Original Approved Country/TerritoryUnited States
Original Approved Date2013/11/01
Country/TerritoryCzechiaBelgiumBulgaria +[45] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteRadboud University Medical CenterRoche Pharma Ag +[19] 
Inactive CompaniesOhsu Knight Cancer Institute
Active IndicationsCentral Nervous System LymphomaGraft vs Host DiseaseLupus Erythematosus, Systemic +[14] 
Inactive IndicationsRichter's SyndromeLymphoproliferative DisordersKidney Failure, Chronic +[9] 

Other Information

ATC CodeL01XC15
Related LinksWikipediaDrugBankKEGG